摘要
目的：
观察MMP-9，TIMP-2在子宫内膜异位症中的表达，并探讨其在子宫内膜异位症发病机制中的作用。
方法：
以28例子宫内膜异位症(内异症)患者为研究对象，取其异位内膜(28例)和在位内膜(25例)，以同期28例正常子宫内膜标本为对照组。采用免疫组化技术，检测MMP-9、TIMP-2在异位内膜、在位内膜和正常子宫内膜组织中的表达。应用统计软件SPSS 11.0对检测结果进行统计学分析，P＜0.05为差异有显著性。
结果：
①MMP-9在内异症的异位及在位内膜组织上皮中的表达均显著高于正常子宫内膜组(P＜0.01)，MMP-9在3组内膜间质中的表达无明显差异(P＞0.05)，而在正常子宫内膜的增殖期中的表达明显高于分泌期(P＜0.05)。②TIMP-2在内异症异位内膜和在位的间质和腺体中阳性染色较弱，强度以(+)为主，明显低于在正常内膜组织(++～+++)，差异均有显著性(P＜0.01，P＜0.05)。③正常子宫内膜与内异症在位内膜组织中TIMP-2的表达均受月经周期的影响而呈现周期性变化，分泌期的表达明显高于增生期(P＜0.05)；而在子宫内膜异位症异位内膜组织中失去周期性变化，增生期与分泌期无显著性差别(P＞0.05)。
结论：
子宫内膜异位症异位和在位内膜组织中MMP-9高表达，TIMP-2低表达，使MMPs与TIMP平衡失调，异位内膜组织侵袭降解ECM的能力增强，从而在子宫内膜异位症中的发生发展中发挥重要作用。
Objective:
To observe the expression of the matrix metalloproteinases-9(MMP-9)and tissue inhibitor of metalloproteinase-2(TIMP-2) in theeutopic and ectopic endometrium from women with and withoutendometriosis, there by to investigate the role of MMP-9 and TIMP-2 in thepathogenesis of endometriosis.
Methods:
Immunohisto-chemical streptavidin-peroxidase (S-P) were employed todetect the protein express of MMP-9 and TIMP-2 in 28 ectopic endometriaand 25 entopic endometria from women with endometriosis and 28 normalcontrol endometrium, and analyze the results by SPSS 11.0 statisticalsoftware, which finds P＜0.05 to be markedly different.
Results:
①The expression of MMP-9 in the epidermis of ectopic endometria and25 entopic endometria from women with endometriosis was significantlyhiger than normal controls (P＜0.01), and the expression of MMP-9 was notobvious difference in endomembrane mesenchymal with 3 groups (P＞0.05),but its expression of MMP-9 in multiplication period with normalendomembrane was significantly higer than progestational stage (P＜0.05).
②The staining of TIMP-2 protein in the stromal and glandular cellsof ectopic and eutopic endometrium in endometriosis were both mildlypositive, and were significantly lower than that of normalendometrium (P＜0.01;P＜0.05).③The expression of TIMP-2 protein wereirrespective of the clinical stage (P＞0.05). The expression of TIMP-2 protein in the eutopic endometrium from women with and withoutendometriosis were all significantly relevant to the phase of themenstrual cycle (P＜0.05), while those in ectopic endometrium was notirrespective of the clinical stage (P＞0.05).
Conclusions:
The increased expression of MMP-9 and decreased expression of TIMP-2in the ectopic endometriosis tissue may lead to the disequilibrium ofMMP-9 and TIMP-2, which contributes to the pathogenesis of endometriosis.present higher expressions and thus lead to vascular accrementition;thedisproportion of MMP-9/TIMP-2 causes the degradation of extracellularmatrix of basal membrane, both of them play a important role in theproduction and development of ectopic endometriotic tissues.
引文
1. Sampson J. Peritoneal endometriosis is due to the menstrual dissemination of endometrial tissue into the peritoneal cavitity[J]. Am J Obstet Gynecol, 1927, 14: 422-469
2. Halme J, Hammond MCP Hulka JF, et al. Retrograde menstruation in healthy women and in patients with endometriosis [J]. Obstet Gynecol, 1984, 64:151-154
3. Keetel WC, Stein RJ. The viability of the cast-off menstrual endometrium. Am J Obsteet Gynecol, 1951,61:440-442
4. Witz CA, Monotoya-Rodriguez IA, Schenken RS. Whole explants of peritoneum and endometrium:a novel model ofthe early endometriosis lesion. Fertil Steril, 1999, 71(1):56-60
5. Whiteside EJ, Jackson MM, Herington AC,et al.Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 are key regulators of extracellular matrix degradation by mouse embryos. Biol Reprod, 2001, 14:1331 — 1337
6. Shimizu M, Saith Y, Ith H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign and lignant human pancreatic tissues, Hum Pathol, 1990, 66(3):468-473
7. Sampson J. Peritoneal endometriosis is due to the menstrual dissemination of endometrial tissue into the peritoneal cavitity. AmJObstet Gynecol, 1927, 14:422-469
8. Spui jbroek MD , Dunselman GA , Menheere PP , Evers JL . Early endometriosis invades the extracellular matrix[J]. Fertil Steril, 1992; 58 (5):929-933.
9. Salamonsen LA, Woolley DE. Matrix metalloproteinase in normal menstruation[J]. Hum Reprod, 1996;11(Suppl 2):124-133.
10. Cross J, Lapiere CM. Collagenolytic activity in amphibfar tissues:a tissue culture assay. Proc Nail Acad Sci, 1962, 48:1197-1204
11. Parson SL, Watson SA, Brown PD, et al. Matrix metalloproteinases [J].Br J Surg, 1997, 84:160-166
12. Velasco G, Pendas AM, Fueyo A, et al. Clonging and character-ization of human MMP-23, a new matrix metalloproteinase predominantly in reproductive tissue and lacking conserved domains in other family members.J Biol Chem, 1999, 274(8):4570-4576
13. Woessner JF JR. Matrix metalloproteinases and their inhibitors in connective tissue remodeling [J].FASEB J, 1991, 5:2145-2154
14. Baker AH, Zaltsman AB, Gerorge SJ, et al. Divergent effects of tissue inhibitor of matrix metalloproteinase-1, -2, -3, overpressions rat vascual smooth muscule cell invasion, proliferation, and death in vitro, TIMP-3promotes apoptosis[J]. J Clin Invest, 1998,101(6): 1478-1487
15. Greene J, WangM, Liu Ye, et al. Molecuar cloning and characterization of human tissue inhibitor of metalloproteina-se-4 [J]. J Biol Chem, 1996, 271(48):30375-80
16．陈必良．基质金属蛋白酶9和14在子宫内膜异位症中的表达[J]．肿瘤防治研究，2003，30(4)；285-288
17. Sharpe Timms KL, Muscolino GM, Bruner KL, et al. Differential expression and localization of tissue inhibitor of metalloproteinasel (TIMP1) In endometrium and endometriosis[J]. FertilSteril, 1996, 66(Suppl):35-36.
18. Bode W, Fernandez Catalan C, Tschesche H, et al. Insights into MMF-TIMP interactions. Cell Mol Life Sci, 1999, 55(4): 639
19. Massova I, Kotra LP, Fridman R, et al. Matrix metalloproteinases:structure sevolution, and diver sification. FASEB, 1998, 12(12):1075
20. Woessner JF JR. Matrix metalloproteinases and their inhibitors in connective tissue remodeling [J].FASEB J, 1991, 5:2145-2154
21. Ray JM, Sterler-Stevenson WG.. TIMP-2 expression modulates human melanoma cell adhesion and motility[J].Ann N Y Acad Sci, 1994,732:233-236
22. LiJnen HR, Ugwu F, Bini A, et al. Generation of an angiostatin-like fragment from plasmingen by stromelysin-1(MMP-1).Biochemistry, 1998,37(14):4699-4711
23．方静．基质金属蛋白酶在妇科肿瘤侵袭和转移中的作用[J]．国外医学妇幼保健分册，2001，12(1)：19-22
24. Hulboy DL, Rufolph LA, Matrisian LM, et al. Matrix metalloproteinases as mediator of reproductive function. Mol Hum Reprod, 2000, 3:27-45
25．王玉玲，其木格．基质金属蛋白酶及抑制物在妇产科的应用．国外医学妇幼保健分册，2005．16(3)：184-186
26．陈华江，王杰军．基质金属蛋白酶的结构及其调节机制．国外医学肿瘤学分册，2001，28(1)：20-23
27．曾仲，韩本立．基质金属蛋白酶组织抑制剂的生物学功能．国外医学分子生物学分册，2000．22(2)：84-87
[1] 吴平，李美芝．基质金属蛋白酶及其抑制物与子宫内膜异位症关系的研究进 展．陕西医学杂志，2005，34，(6)：723-721．
[2] Sillem M, Hahn U, Coddington CC. et al. Ectopic growth of endometrium depends on its structural integrity and proteolytic activity, in the cynomolgus monkey (Macaca fascicularis)model of endometriosis. Fertil Steril, 1996; 66(3): 468.
[3] Curry Jr TE, Osteen KG. Cyclic changes in the matrix metallo proteinase system in the ovary and uterus. Biol Reprod, 2001, 64:1285-1296.
[4] Lee E, VaughanDE, Parikh SH, et al. Regulation of matrix metallo proteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in Cultured human vascular smooth muscle cell. Circ Res, 1996:78(1):5.
[5] Ries C, Petrides PE. Cytokine regulation of matrix metallo proteinases activity and its regulatory dysfunction in disease. BiOl Chem, 1995, 37(6):345.
[6] Lin F, Wise GE. Efect of epidermal growth factor on expression of transforming growth factor-betal mRNA in stellate reteculum cells of rat mandibular molars. Dev Dyn, 1993, 198(1):22.
[7] Galis ZS. Microscopic localization of active proteinases by insitu-zymo-graph: detection of matrix metalloproteinases activity in vascular tissue. FASEB J, 1995, 9(10):974.
[8] Lmren S, Rohn DB, Shimada et al. Overexpress tissue inhibitor of metalloproteinases-2 by retroviral mediated gene transfer. Res, 1996, 56:2891.
[9] 邱芳，高雪梅．基质金属蛋白酶及其抑制物与子宫内膜异位症的发生．实用妇产科杂志，2005，21(5)：273-275．
[10] 邱晓红，李荷莲．基质金属蛋白酶及其抑制因子与子宫内膜异位症的研究现状与展望．中国实验诊断学，2003，7，(5)：459-462．
[11] Cox KE. Diferential regulation matrix metallo prot-einase-3 gene expression in erdorrolie lesiom compared with dometrium. Biol Repld, 2001, 65(4):1297-1303.
[12] Goffin F, Munaut C. Frankenne F, et al. Expression pattern of metallo proteinases and tissue inhibitors of matrix metallo proteinases in cycling human endometrium. Biol Reprod, 2003, 69 (3):976-984.
[13] Curry Jr TE, Osteen KG. Cyclic changes in the matrix metallo proteinase system in the ovary and uterus. Biol Reprod, 2001, 64:1285-1296.
[14] Ueda M, Yamashita Y, Takehara M, et al. Gene expression of adhesion molecules and matrix metal-oproteinases in endometriosis. Gynecol En21docrinol, 2002, 16 (5):391-402.
[15] Singer CF, Kronsteiner N, Marton E, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differ rentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat, 2002, 72:69-77.
[16] Kleiner DE, Steler-WG. Matrix metallo proteinases and metas. tasis[J].Cancer Chemother Pham Jmacol, 1999, 43:S42-51.
[17] 于云英，郭新华，钱金花等．基质金属蛋白酶-9及其组织抑制剂TIMP-3在子宫内膜异位症的表达．现代妇产科进展，2003，12(1)：23-26．
[18] Ria R, Loverro G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 agree with progression of ovarian endometriosis. Eur J Clin Invest, 2002, 32(3):199-206.
[19] Chung HW, Lee JY, Moon HS, et al. Matrixetalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril, 2002, 78(4):787-795.
[20] Mitsiades N, Yu WH, Poulaki V, et al. Matrix metalloprote- inases-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res, 2001, 61(2): 577- 581.
[21] Mizumoto H , Saito T, Ashihara K, et al. Expression of matrix metallproteinases in ovarian endometriomas:immunohisto chem ical study and enzyme immunoassay. Life Sci, 2002, 71(3):259-273.
[22] Bruner-Tran KL, Eisenberg E , Yeaman GR, et al. Steroid and Cytokine Regulation of Matrix Metalloproteinase Expression in Endometriosis and the Establishment of Experimental Endometrio- sis in Nude Mice, The Journal of Clinical Endocrinology &Metabolis hm. 2002, 87(10):4728-4791.